PAION is a specialty pharmaceutical company that develops innovative products for sedation and anesthesia including commercialization.  

 

Learn more About PAION

Remimazolam

PAION’s lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic drug candidate which is in the final stage of clinical development for use in procedural sedation in the U.S. Remimazolam has been investigated in more than 1,500 patients worldwide. 

PAION's Remimazolam

news

08/09/2017

Presentation H1 2017

Presentation H1 2017

Read more
08/09/2017

PAION AG reports financial results for the first half-year of 2017

PAION AG reports financial results for the first half-year of...

Read more
08/09/2017

Consolidated Financial Interim Report for the First Half Year 2017

Consolidated Financial Interim Report for the First Half-Year...

Read more
03/09/2017

Press Release: PAION AG: Change in Management Board

PAION AG: Change in Management Board

Read more
02/28/2017

Press Release: PAION AG announces successful completion of capital increase with...

PAION AG announces successful completion of capital increase with...

Read more
02/07/2017

Press Release: PAION AG: Capital increase; preliminary, unaudited key group...

PAION AG: Capital increase; preliminary, unaudited key Group...

Read more
12/21/2016

Press Release: PAION announces clinical development progress with remimazolam by...

PAION announces clinical development progress with remimazolam by...

Read more
10/19/2016

Press Release: Positive Remimazolam phase III colonoscopy results presented at...

Positive Remimazolam phase III colonoscopy results presented at...

Read more
09/22/2016

Press Release: Remimazolam Phase III colonoscopy data to be presented at the...

Remimazolam Phase III colonoscopy data to be presented at the...

Read more
09/06/2016

Press Release: PAION announces clinical development progress with remimazolam by...

PAION announces clinical development progress with remimazolam by...

Read more
06/29/2016

Press Release: PAION completes private placement in the amount of EUR 9.6...

PAION completes private placement in the amount of EUR 9.6...

Read more
06/19/2016

Press Release: PAION reports positive remimazolam headline data in pivotal U.S....

PAION reports positive remimazolam headline data in pivotal U.S....

Read more
04/11/2016

Press Release: PAION successfully completes patient recruitment in Phase III...

PAION successfully completes patient recruitment in Phase III...

Read more

PAION Chart